X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (36) 36
oncology (34) 34
humans (30) 30
female (24) 24
middle aged (24) 24
aged (22) 22
adult (20) 20
melanoma (17) 17
chemotherapy (16) 16
ovarian cancer (16) 16
ovarian neoplasms - drug therapy (14) 14
multicenter (13) 13
immunotherapy (12) 12
open-label (12) 12
survival (12) 12
treatment outcome (12) 12
cancer (11) 11
care and treatment (11) 11
germ-line mutation (10) 10
metastasis (10) 10
ovarian neoplasms - genetics (10) 10
aged, 80 and over (9) 9
antineoplastic agents - therapeutic use (9) 9
brca1 protein - genetics (9) 9
brca2 protein - genetics (9) 9
male (9) 9
ovarian neoplasms - pathology (9) 9
phthalazines - adverse effects (9) 9
piperazines - adverse effects (9) 9
poly polymerase (9) 9
antineoplastic agents - adverse effects (8) 8
disease-free survival (8) 8
hematology, oncology and palliative medicine (8) 8
ipilimumab (8) 8
melanoma - pathology (8) 8
patients (8) 8
tumors (8) 8
analysis (7) 7
carcinoma (7) 7
immunology (7) 7
melanoma - therapy (7) 7
neoplasm staging (7) 7
phthalazines - therapeutic use (7) 7
piperazines - therapeutic use (7) 7
solid tumors (7) 7
expression (6) 6
lymphocytes, tumor-infiltrating - immunology (6) 6
metastatic melanoma (6) 6
olaparib (6) 6
ovarian neoplasms - mortality (6) 6
pembrolizumab (6) 6
retrospective studies (6) 6
therapy (6) 6
cancer therapies (5) 5
clinical trials (5) 5
double-blind method (5) 5
interleukin-2 (5) 5
melanoma - immunology (5) 5
mutation (5) 5
neoplasm recurrence, local - drug therapy (5) 5
nivolumab (5) 5
obstetrics & gynecology (5) 5
phthalazines - administration & dosage (5) 5
piperazines - administration & dosage (5) 5
platinum (5) 5
poly polymerase inhibitors - administration & dosage (5) 5
prognosis (5) 5
survival analysis (5) 5
toxicity (5) 5
tumor-infiltrating lymphocytes (5) 5
young adult (5) 5
abridged index medicus (4) 4
antineoplastic agents - administration & dosage (4) 4
biomarkers (4) 4
breast cancer (4) 4
cutaneous melanoma (4) 4
disease progression (4) 4
diseases (4) 4
drug therapy (4) 4
follow-up studies (4) 4
genes, brca1 (4) 4
genes, brca2 (4) 4
immunotherapy, adoptive - methods (4) 4
kaplan-meier estimate (4) 4
medicine & public health (4) 4
melanoma - drug therapy (4) 4
neoplasm grading (4) 4
ovarian carcinoma (4) 4
phase-2 (4) 4
poly polymerase inhibitors - adverse effects (4) 4
poly polymerase inhibitors - therapeutic use (4) 4
relapse (4) 4
repair (4) 4
research (4) 4
response rates (4) 4
responses (4) 4
studies (4) 4
trial (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
antitumor activity (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4095 - 4106
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Oncogene, ISSN 0950-9232, 08/2014, Volume 33, Issue 35, pp. 4424 - 4432
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 11/2017, Volume 147, Issue 2, pp. 267 - 275
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 06/2019, Volume 154, pp. 231 - 232
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_5
Abstract Background Pembrolizumab (pembro) provides durable responses in patients (pts) with MSI-H cancers and is approved in the US/Japan for the treatment of... 
Journal Article